News | November 19, 2025
Sudeep Pharma eyes Rs. 895 crore fundraising from debut on bourses
The issue comprises a fresh issue of Rs. 95 crore and targeting a total raise of around Rs. 895 crore
The issue comprises a fresh issue of Rs. 95 crore and targeting a total raise of around Rs. 895 crore
_256_384.png)
India presents one of the world’s largest untapped opportunities for neurovascular screening
The patent will lock in broad protection for the company’s lead therapy CardiolRx and its novel subcutaneous candidate CRD-38
The cleared system pairs a flexible nitinol implant with a deployable prong-locking mechanism, delivering rotational and length stability
The study met its primary endpoint, demonstrating a statistically significant and clinically meaningful improvement in invasive disease-free survival
This move positions the U.S.-based consumer healthcare company for a significantly larger role in the rapidly expanding at-home and retail diagnostic testing market
Under the agreement, Evonik will distribute InVitria’s blood-free rHSA portfolio to its biopharma customers
Stivarga is the standard third-line treatment for metastatic colorectal cancer, gastrointestinal stromal tumors, and hepatocellular carcinoma
Merus has licensed Halozyme’s proprietary ENHANZE technology to develop and commercialize subcutaneous formulations of petosemtamab
Developed in partnership with the Johns Hopkins Applied Physics Laboratory (APL), the module is built around a multi-segment RT-PCR method with integrated indexing
Subscribe To Our Newsletter & Stay Updated
